MX2023004831A - Metodos para reducir tau en sujetos humanos. - Google Patents
Metodos para reducir tau en sujetos humanos.Info
- Publication number
- MX2023004831A MX2023004831A MX2023004831A MX2023004831A MX2023004831A MX 2023004831 A MX2023004831 A MX 2023004831A MX 2023004831 A MX2023004831 A MX 2023004831A MX 2023004831 A MX2023004831 A MX 2023004831A MX 2023004831 A MX2023004831 A MX 2023004831A
- Authority
- MX
- Mexico
- Prior art keywords
- tau
- methods
- human subjects
- reducing tau
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105804P | 2020-10-26 | 2020-10-26 | |
| PCT/EP2021/079543 WO2022090158A1 (en) | 2020-10-26 | 2021-10-25 | Methods of reducing tau in human subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004831A true MX2023004831A (es) | 2023-07-12 |
Family
ID=78402146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004831A MX2023004831A (es) | 2020-10-26 | 2021-10-25 | Metodos para reducir tau en sujetos humanos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220127345A1 (https=) |
| EP (1) | EP4232155A1 (https=) |
| JP (1) | JP2023546504A (https=) |
| KR (1) | KR20230093499A (https=) |
| CN (1) | CN116916955A (https=) |
| AU (1) | AU2021367878A1 (https=) |
| CA (1) | CA3199806A1 (https=) |
| IL (1) | IL302386A (https=) |
| MX (1) | MX2023004831A (https=) |
| TW (1) | TW202233666A (https=) |
| WO (1) | WO2022090158A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| JP7379764B1 (ja) | 2022-08-09 | 2023-11-15 | レール・リキード－ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード | 空気分離装置および空気分離方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP6214161B2 (ja) * | 2009-12-21 | 2017-10-18 | ジェネンテック， インコーポレイテッド | 抗体製剤 |
| ITMI20120814A1 (it) * | 2012-05-11 | 2013-11-12 | Diego Dolcetta | Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CN117820467A (zh) * | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
| TWI771389B (zh) * | 2017-03-16 | 2022-07-21 | 美商健生生物科技公司 | 抗phf-tau抗體及其用途 |
| MA53338A (fr) * | 2018-03-05 | 2022-01-05 | Janssen Pharmaceutica Nv | Dosages pour détecter la neurodégénérescence |
| WO2020223279A1 (en) * | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
| EP4232472A1 (en) * | 2020-10-26 | 2023-08-30 | JANSSEN Pharmaceutica NV | Method of safe administration of anti-tau antibody |
-
2021
- 2021-10-25 WO PCT/EP2021/079543 patent/WO2022090158A1/en not_active Ceased
- 2021-10-25 AU AU2021367878A patent/AU2021367878A1/en active Pending
- 2021-10-25 MX MX2023004831A patent/MX2023004831A/es unknown
- 2021-10-25 IL IL302386A patent/IL302386A/en unknown
- 2021-10-25 EP EP21798703.1A patent/EP4232155A1/en active Pending
- 2021-10-25 JP JP2023525044A patent/JP2023546504A/ja active Pending
- 2021-10-25 TW TW110139444A patent/TW202233666A/zh unknown
- 2021-10-25 US US17/509,889 patent/US20220127345A1/en active Pending
- 2021-10-25 CN CN202180087530.2A patent/CN116916955A/zh active Pending
- 2021-10-25 CA CA3199806A patent/CA3199806A1/en active Pending
- 2021-10-25 KR KR1020237017869A patent/KR20230093499A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202233666A (zh) | 2022-09-01 |
| US20220127345A1 (en) | 2022-04-28 |
| KR20230093499A (ko) | 2023-06-27 |
| IL302386A (en) | 2023-06-01 |
| CA3199806A1 (en) | 2022-05-05 |
| AU2021367878A1 (en) | 2023-06-22 |
| JP2023546504A (ja) | 2023-11-02 |
| EP4232155A1 (en) | 2023-08-30 |
| WO2022090158A1 (en) | 2022-05-05 |
| CN116916955A (zh) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY209590A (en) | Anti-msr1 antibodies and methods of use thereof | |
| AU2018263862A1 (en) | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof | |
| MX2024011615A (es) | Anticuerpos de union a cd3. | |
| MX2024005027A (es) | Anticuerpos de union a cd3. | |
| WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| WO2019186276A3 (en) | Antibody-based methods of detecting and treating alzheimer's disease | |
| WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
| MX2023004831A (es) | Metodos para reducir tau en sujetos humanos. | |
| MX2020008718A (es) | Anticuerpos de union a bcma y usos de los mismos. | |
| WO2019204462A3 (en) | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs | |
| MX2025003476A (es) | Anticuerpos anti-il-27 y usos de los mismos | |
| WO2018116267A3 (en) | Methods of treatment with anti-factor xi/xia antibodies | |
| MY204235A (en) | Antibodies specific for cd3 and uses thereof | |
| WO2021087368A3 (en) | Anti-cd45 antibodies and conjugates thereof | |
| WO2014007982A3 (en) | C-terminal and central epitope a-beta antibodies | |
| MX2023004280A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. | |
| WO2020247929A8 (en) | High affinity anti-cd3 antibodies, and methods for their generation and use | |
| EP4653462A3 (en) | Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b | |
| MX2019011624A (es) | Metodos y composiciones para la reduccion de la inmunogenicidad. | |
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
| CA3242661A1 (en) | Compositions and methods for treatment of thyroid eye disease | |
| WO2023133485A3 (en) | Compositions and methods for treatment of thyroid eye disease |